Table 4.
Potential risk factors for the development of AACG in the AACG group compared with the N-AACG group during phase A.
| Potential risk factors | AACG group (N = 21) | N-AACG group (N = 69) | χ 2/t | P |
|---|---|---|---|---|
| Sex, n (%) | 6.579 | 0.010b | ||
| Female | 17 (33.33) | 34 (66.67) | ||
| Male | 4 (10.26) | 35 (89.74) | ||
| Age, years (mean ± SD) | 65.86 ± 8.63 | 58.58 ± 17.01 | −1.883 | 0.063a |
| COVID-19 status, n (%) | 18.378 | <0.001c | ||
| Negative | 1 (2.44) | 40 (97.56) | ||
| Positive | 20 (40.82) | 29 (59.18) | ||
| Glaucoma started after testing positive for COVID-19, n (%) | 20.649 | <0.001b | ||
| No | 7 (10.77) | 58 (89.23) | ||
| Yes | 14 (56.00) | 11 (44.00) | ||
| Adverse behavior, n (%) | — | 0.233c | ||
| No | 20 (22.47) | 69 (77.53) | ||
| Yes | 1 (100.00) | 0(0.0) | ||
| History of medication use, n (%) | 6.988 | 0.008b | ||
| No | 9 (15.00) | 51 (85.00) | ||
| Yes | 12 (40.00) | 18 (60.00) | ||
| Monocular/binocular involvement, n (%) | 0.034 | 0.853b | ||
| Monocular | 9 (24.32) | 28 (75.68) | ||
| Binocular | 12 (22.64) | 41 (77.36) | ||
| Non-COVID-19 systemic diseases, n (%) | 1.860 | 0.173b | ||
| No | 17 (27.42) | 45 (72.58) | ||
| Yes | 4 (14.29) | 24 (85.71) | ||
Note. n (%), Number of patients with glaucoma; %: ratio of the patients. SD = standard deviation. An independent-sample t-test (a) for age, Pearson's chi-square test (b), and Fisher's exact test (c) for categorical variables were used to test the difference between the AACG and N-AACG groups. AACG, acute angle-closure glaucoma; N-AACG, nonacute angle-closure glaucoma.